EGFR and non-small cell lung carcinoma: Similarly, monotherapy with new‐generation EGFR‐TKIs with more specific activity for the T790M mutation, such as osimertinib, show better adverse event profiles in clinical trials, and the outcomes are encouraging in patients with advanced NSCLC who develop a secondary T790M mutation and EGFR‐TKI resistance.15 Rebiopsy might be valuable in decision‐making for follow‐up treatment.